Home LiteratureArticle Details
PMID: 8121569 Published · ppublish English Clinical Trial Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis.

Neurosurgery ·Vol. 34 ·No. 1 ·1994-01-00 ·Pages 45-60; discussion 60-1

Albert FK, Forsting M, Sartor K, Adams HP, Kunze S

Abstract

In the vast majority of studies that address the role of surgery in the management of high-grade gliomas, the degree of tumor removal accomplished is solely based on the intraoperative perception of the neurosurgeon. Despite its fundamental importance for a comparison of different treatment modalities, little systematic effort has been made to evaluate the residual gross tumor by neuroimaging methods immediately after surgery. We report the results of a prospective study using contrast-enhanced computed tomography and magnetic resonance imaging (MRI) to monitor 60 patients after the resection of a high-grade glioma. In each case, the first scans were obtained between Days 1 and 5 after surgery, followed by serial imaging every 2 to 3 months, usually until the condition of the patient deteriorated severely or the patient died. Gadolinium-enhanced MRI proved to be extremely valuable for assessing gross residual tumor when performed during Days 1 to 3 after the resection of a preoperatively enhancing high-grade glioma. This timing avoided surgically induced contrast enhancement and minimized interpretative difficulties. In delineating residual tumor, MRI was vastly superior to computed tomography. About 80% of tumor "recurrences" emerged from definitely enhancing remnants, as revealed by early postoperative MRI. The neurosurgeon's estimation of gross tumor burden reduction could be shown to be much less accurate (by a factor of 3) than the postoperative assessment by modern neuroimaging. In our series, residual tumor enhancement was the most predictive prognostic factor of survival in patients with glioblastoma, followed by radiotherapy. Patients with a residual tumor postoperatively had a 6.595-times higher risk of death in comparison to patients without a residual tumor. Patients undergoing radiotherapy had a 0.258-times lower risk of death in comparison to patients who were not treated with radiation. Concerning survival, the prognostic significance of both variables surpassed age and performance.

MeSH Terms
Brain Neoplasms/diagnosis,mortality,surgery Combined Modality Therapy Contrast Media Cranial Irradiation Female Follow-Up Studies Gadolinium DTPA Glioblastoma/diagnosis,surgery Humans Iohexol Magnetic Resonance Imaging Male Middle Aged Neoplasm Recurrence, Local/diagnosis,mortality,surgery Organometallic Compounds Pentetic Acid/analogs & derivatives Postoperative Complications/diagnosis,surgery Prognosis Prospective Studies Survival Rate Tomography, X-Ray Computed
Chemicals
Contrast Media Organometallic Compounds Iohexol Pentetic Acid Gadolinium DTPA
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Albert F K
Department of Neurosurgery, University of Heidelberg, Germany.
Forsting M
Sartor K
Adams H P
Kunze S
Article Info
Journal
Neurosurgery
Abbr.
Neurosurgery
ISSN
0148-396X
Published
1994-01-00
Pages
45-60; discussion 60-1
Language
English
Region
United States
NLM ID
7802914
Subset
IM
Grants
NCI NIH HHS · R01-CA41582 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com